💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Futibatinib

CHEMBL3701238 Phase 4 Approved Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
418.4 g/mol
LogP
2.0
Phase
4

This oral medication selectively and irreversibly inhibits FGFR1-4, receptors that drive the growth of certain cancers when mutated or overactive. It is used to treat cholangiocarcinoma with FGFR2 gene rearrangements and is being studied in bladder and breast cancers with FGFR alterations.

Molecular Weight

418.4000 g/mol

LogP

2.00

TPSA

108.00 Ų

Lipinski RO5

Pass

Therapeutic Areas

Bladder Cancer Breast Cancer Colorectal Cancer Lymphoma Non-Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Prostate Cancer Thyroid Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C=CC(=O)N1CC[C@H](n2nc(C#Cc3cc(OC)cc(OC)c3)c3c(N)ncnc32)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H22N6O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
Rotatable Bonds

                        
6

                    

                    
                    
                    

                        
Heavy Atoms

                        
31

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
This oral medication selectively and irreversibly inhibits FGFR1-4, receptors that drive the growth of certain cancers when mutated or overactive. It is used to treat cholangiocarcinoma with FGFR2 gene rearrangements and is being studied in bladder and breast cancers with FGFR alterations.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Futibatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3701238.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 71621331.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.